Brigatinib
Brigatinib-2001
Phase 2 small_molecule completed
Quick answer
Brigatinib for ALK-positive Advanced NSCLC is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- ALK-positive Advanced NSCLC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed